Stifel Reiterates Buy Rating on Precision BioSciences (DTIL) Over Equity Raise; Novartis Deal Could Net "Up to $1.4B"

June 22, 2022 6:13 AM EDT Send to a Friend
Stifel analyst Benjamin J. Burnett reiterated a Buy rating on Precision BioSciences Inc. (NASDAQ: DTIL), after the company announced a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login